Who
Robert Connelly
CEO, President and Director
Company insider
Files Form 4 as: CEO, President and Director, Elicio Therapeutics.
In numbers
- Trades disclosed
- 9
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Feb 2024
- Last trade
- 16 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 17 Jul 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,944 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,944 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio TherapeuticsBiotechnology | SEC FORM 4 Code A | —73,600 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —147,200 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —147,200 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELTX Elicio TherapeuticsBiotechnology | SEC FORM 4 Code A | —73,600 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,600 at $0.00 | filing |
| 30 Sep 2024filed 2 Oct 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,600 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,137 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.